Overview

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether Gemcitabine versus Gemcitabine and TH-302 are effective in the treatment of subjects with first-line metastatic pancreatic adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Threshold Pharmaceuticals

Collaborator:

PRA Health Sciences

Treatments:

Gemcitabine
Phosphoramide Mustards